Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Melissa PalmerArie RegevKeith LindorMark I AviganLara Dimick-SantosWilliam TreemJohn F MarcinakJames H LewisFrank A AnaniaDaniel SeekinsBenjamin L ShneiderNaga ChalasaniPublished in: Alimentary pharmacology & therapeutics (2019)
This paper provides a framework for the approach to detection, assessment and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver disease.
Keyphrases
- drug induced
- liver injury
- clinical trial
- liver failure
- pulmonary embolism
- respiratory failure
- loop mediated isothermal amplification
- healthcare
- real time pcr
- clinical practice
- primary care
- label free
- adverse drug
- aortic dissection
- liver fibrosis
- phase ii
- open label
- emergency department
- hepatitis b virus
- electronic health record